Therapeutic effect of entecavir or tenofovir combined with PEG-IFN α-2b on patients with chronic hepatitis B hypoviremia

Abstract

Abstract: Objective To explore the effect of entecavir or tenofovir combined with PEG-IFN α-2b on treating patients with chronic hepatitis B hypoviremia.Methods From September 2017 to October 2021, 52 patients with chronic hepatitis B who had not previously received antiviral therapy were treated with entecavir or tenofovir combined with PEG-IFN α-2b for 48 weeks. The researchers compared the baseline characteristics, blood cell changes and virological changes of patients in entecavir group and tenofovir group.Results There were no significant differences between the two groups at baseline. Red blood cell count, lymphocyte count and neutrophil count showed a downward trend , but there was no significant difference between the two groups. At the 48th week of treatment, the negative conversion rates of HBeAg and HBV DNA in tenofovir group were 46.2% (12/26) and 84.6% (22/26), which were significantly higher than those of entecavir group [11.5% (3/26) and 57.7% (15/26) (P<0.05)].Conclusion In patients with HBeAg-positive chronic hepatitis B, treatment with tenofovir combined with PEG-IFN α-2b was better than treatment with entecavir combined with PEG-IFN α-2b after using PEG-IFN α-2b alone for 12 weeks.

Key words: Chronic hepatitis B, Entecavir, Tenofovir

ZHANG Pei-yuan, LEI Xue, WANG Mei-yu. Therapeutic effect of entecavir or tenofovir combined with PEG-IFN α-2b on patients with chronic hepatitis B hypoviremia[J]. Chinese Hepatolgy, 2023, 28(8): 947-949.

References

[1] Zheng SM, Lin N, Tang SH, et al. Isolated hepatic tuberculosis associated with portal vein thrombosis and hepatitis B virus coinfection: a case report and review of the literature. World J Clin Cases, 2021, 9(30): 9310-9319.
[2] Hur MH, Park MK, Cheuk-Fung Yip T, et al. Personalized antiviral drug selection in chronic hepatitis B patients using a machine learning model: a multinational study. Am J Gastroenterol, 2023.
[3] Matsui M, Asai A, Ushiro K, et al. Hb surface antigen level as a useful predictor for the treatment response to tenofovir alafenamide in nucleoside analogue naive chronic hepatitis B. In Vivo, 2023, 37(2): 726-733.
[4] Li MY, Li TT, Li KJ, et al. Type 2 diabetes mellitus characteristics affect hepatocellular carcinoma development in chronic hepatitis B patients with cirrhosis. World J Clin Cases, 2023, 11(5): 1009-1018.
[5] Liu R, Yang L, Jiang T, et al. Hepatitis b core-related antigen serum levels may be a predictor of acute flare of chronic hepatitis B among pregnant women in the immune-tolerant phase of chronic hbv infection after short-course antiviral therapy. Virulence, 2023, 14(1): 2186335.
[6] Jang TY. Letter: improved alanine aminotransferase level in patients with chronic hepatitis B without cirrhosis and low viral load treated with nucleotide/nucleoside analogues. Aliment Pharmacol Ther, 2023, 57(5): 587-588.
[7] Li YJ, Chen EQ. Editorial: baseline hepatitis B virus haplotype number may help predict a functional cure in patients with chronic hepatitis B treated with nucleotide analogues. Aliment Pharmacol Ther, 2023, 57(5): 581-582.
[8] Zhang Q, Liu X, Pang X, et al. Recovery of host adaptive immune function promoted the reduction of hepatitis B surface antigen in nucleoside analog-experienced chronic hepatitis B patients with low hepatitis b surface antigen levels. Cytokine, 2023, 164: 156140.
[9] Wagner J, Littlejohn M, Revill PA. Editorial: baseline hepatitis B virus haplotype number may help predict a functional cure in patients with chronic hepatitis B treated with nucleotide analogues-authors' reply. Aliment Pharmacol Ther, 2023, 57(5): 583-584.
[10] Nardone A, Nerlander L, Duffell E, et al. A pilot sentinel surveillance system to monitor treatment and treatment outcomes of chronic hepatitis B and C infections in clinical centres in three european countries, 2019. Euro Surveill, 2023, 28(6).
[11] Lin Y, Shen G, Xie S, et al. Dynamic changes of the proportion of hla-dr and cd38 coexpression subsets on t lymphocytes during ifn-based chronic hepatitis B treatment. Front Immunol, 2022, 13: 1116160.

[1]	ZHANG Jia-qi, WANG Zai-chao, YANG Jia-yao, WANG Xiao-meng, ZHAO Yu. Construction and validation of the risk prediction model for secondary hepatic encephalopathy in patients with chronic hepatitis B and cirrhosis [J]. Chinese Hepatolgy, 2023, 28(8): 916-920.
[2]	ZHAO Xin-yi, SUN Jie, XU Wei-xin. Effect of serum Maresin-1 level on nonalcoholic fatty liver disease [J]. Chinese Hepatolgy, 2023, 28(7): 806-809.
[3]	AN Bao-yan, GUO Qing, FENG Ming-yang, XU Yu-min, CAI Wei, XIE Qing, WANG Hui. A prospective study of the efficacy of entecavir combined with carvedilol in the treatment of hepatitis B cirrhosis combined with esophagogastric varices [J]. Chinese Hepatolgy, 2023, 28(6): 646-648.
[4]	LI Fen, WEI Shu-zhen, LI Liang, MO Yu-ling, FU Xiao-fan, LEI Ren-guo, ZHENG Zi-yu. The risk of hepatitis attack and the clinical value of NAs intervention in pregnant women with HBV infection during pregnancy and postpartum [J]. Chinese Hepatolgy, 2023, 28(5): 527-529.
[5]	YANG Mei, LV Yun-hai. Establishment of an accurate prediction system for clinical endpoint events during antiviral therapy for chronic hepatitis B [J]. Chinese Hepatolgy, 2023, 28(4): 423-427.
[6]	CAO Jing-jing, LI Rong, LI Jing, PAN Feng. Therapeutic effect of nucleoside/nucleotide analogues on HBeAg-negative chronic hepatitis B patients with normal or slightly elevated alanine aminotransferase [J]. Chinese Hepatolgy, 2023, 28(4): 432-435.
[7]	CHEN Wei-hua, TIAN Ling-rong, XI Zhen. Influencing factors of disease progression in patients with chronic hepatitis B treated with long-term antiviral therapy [J]. Chinese Hepatolgy, 2023, 28(4): 436-439.
[8]	LIANG Heng-kai, WEI Lu, SU Ming-hua, LIANG Huan, HU Bo-bin, HUANG Jian-fang, CHEN Yan-hong, JIANG Jian-ning. Clinical study on the efficacy and safety of oral nucleos(t)ide analogues in HBV mother-to-infant obstruction of pregnant women with high viral load [J]. Chinese Hepatolgy, 2023, 28(3): 296-298.
[9]	SU Pei-hua, WEI Meng-ping, ZHAO Cai-yan. Influence on chronic hepatitis B combined with nonalcoholic fatty liver disease on the development of hepatocellular carcinoma and all-cause mortality: A meta-analysis [J]. Chinese Hepatolgy, 2023, 28(3): 299-304.
[10]	XIE Shuang-shuang, CHENG Wen-jin, JIAO Jun-xia, LIU Xiao-yan, LIU Li. Analysis on risk factors of osteoporosis in chronic hepatitis B patients treated with nucleos(t)ide analogues [J]. Chinese Hepatolgy, 2023, 28(3): 309-312.
[11]	GU Lin-lin, HU Rui, DOU Yu-ming, XIAO Li. Predictors associated with functional cure in HBeAg-negative chronic hepatitis B patients treated with pegylated interferon α-2b [J]. Chinese Hepatolgy, 2023, 28(3): 313-319.
[12]	HUANG Yong-xu, CHEN Chao, BAO Zi-hong, ZHOU Xiao-hui. Influencing factors of low-level viremia in patients with chronic hepatitis B treated with Entecavir [J]. Chinese Hepatolgy, 2023, 28(3): 320-324.
[13]	LU Qiu-yan, LU Yan-hui, XU Cheng-run. Diagnostic value of liver stiffness combined with spleen stiffness detected by transient elastography for pathological stage of liver fibrosis in chronic hepatitis B patients [J]. Chinese Hepatolgy, 2023, 28(3): 325-329.
[14]	LI Wan, HAN Yan-xia, XIE Shou-zhen, MA Ying-cai, YANG Yong-geng, LI Ping-ying. The impact of weight loss on the severity of liver fibrosis and fatty liver in patients with chronic hepatitis B and/or non-alcoholic fatty liver disease [J]. Chinese Hepatolgy, 2023, 28(2): 203-206.
[15]	DENG Hao-hui, LOU Yan, LI Xiao-qiang, QIU Jiu-xiang. The relationship between single nucleotide polymorphisms of ITPA gene and thrombocytopenia induced by pegylated interferon therapy in chronic hepatitis C and chronic hepatitis B patients [J]. Chinese Hepatolgy, 2023, 28(1): 95-99.